Log in to your account:
Gilead Sciences (GILD) Submits NDA for Filgotinib for Treatment of Adults With Rheumatoid Arthritis in Japan
October 8, 2019 6:21 AM
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the New Drug Application (NDA) for filgotinib, an investigational, oral, selective JAK1 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Gilead Sciences Submits New Drug Application for Filgotinib for the Treatment of Adults With Rheumatoid Arthritis in Japan
October 8, 2019 2:00 AM